National Health (Weighted average disclosed price main disclosure cycle) Amendment Determination 2013 (No. 2) (No. PB 37 of 2013) (Cth)

PB 37 of 2013

National Health (Weighted average disclosed price – main disclosure cycle) Amendment Determination 2013 (No. 2)

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this amendment determination under subsection 99ADB(4) of the National Health Act 1953.

Dated     4   July 2013

FELICTY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

1. Name of Determination

(1)     This Determination is the National Health (Weighted average disclosed price – main disclosure cycle) Amendment Determination 2013 (No. 2).

(2)     This Determination may also be cited as PB 37 of 2013.

1. Commencement

This Determination commences on the day after it is registered.

3              Amendments to PB 26 of 2013

Schedule 1 amends the National Health (Weighted average disclosed price – main disclosure cycle) Determination 2013 (No. 1) (PB 26 of 2013).

Schedule 1             Amendments

[1]      Schedule 1

omit:

317 Etoposide Powder for I.V. infusion 1 g (as phosphate) Injection Etopophos 174.65

Insert:

317 Etoposide Powder for I.V. infusion 1 g (as phosphate) Injection Etopophos 174.62

omit:

319 Etoposide Solution for I.V. infusion 100 mg in 5 mL vial Injection Etoposide Ebewe 17.47

insert:

319 Etoposide Solution for I.V. infusion 100 mg in 5 mL vial Injection Etoposide Ebewe 87.33

Note

1.       All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See